IRZ-01
/ Irazu Oncology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
IRZ-01: A self-adjuvanted outer membrane vesicle vaccine targeting CEA and MUC1 for colorectal cancer immunotherapy
(AACR 2026)
- "IRZ-01 is a potent, self-adjuvanted OMV vaccine that induces robust CEA/MUC1-specific humoral and cellular immunity and delivers strong single-agent efficacy in syngeneic tumor models."
Clinical • IO biomarker • Colorectal Cancer • Oncology • Solid Tumor • CEACAM5 • IFNG • MUC1 • TLR2 • TLR4
1 to 1
Of
1
Go to page
1